ABIOMED

Abiomed is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DANVERS, Mass.--(BUSINESS WIRE)--TCT 2021 showcases data and clinical studies supporting the use of Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure.

TCT 2021 to Highlight Improved Patient Outcomes with Impella's Small, Smart and Connected Technology

Abiomed's (ABMD) CEO Mike Minogue on Q2 2022 Results - Earnings Call Transcript

Abiomed (ABMD) delivered earnings and revenue surprises of 5.10% and -0.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) Q2 Earnings Beat Estimates

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q2 fiscal year 2022 revenue of $248 million, up 18% year over year.

Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year

Abiomed (NASDAQ:ABMD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement.

Abiomed's Earnings Outlook

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.

Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Abiomed (ABMD) Q2 Earnings Expected to Decline

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed second quarter fiscal 2022 earnings and conference call notification.

Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification

Abiomed (ABMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Abiomed (ABMD) Stock Jumps 5.9%: Will It Continue to Soar?

Abiomed's strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company's Impella range of micro heart pumps will continue to see increasing adoption globally.

Abiomed: Impella Will Continue To Drive Revenue Growth

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?

Abiomed (ABMD) Up 6% Since Last Earnings Report: Can It Continue?

Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.

Abiomed's (ABMD) Impella ECP Gets FDA's Breakthrough Device Tag

The FDA has granted breakthrough device designation to Abiomed Inc's (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. Abiomed designed the Impella ECP heart pump to be compatible with small-bore access and closure techniques.

Smallest Heart Pump From Abiomed Gets FDA Breakthrough Device Tag

DANVERS, Mass.--(BUSINESS WIRE)--The U.S. Food and Drug Administration has granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.

FDA Grants Breakthrough Device Designation to Impella ECP, the World's Smallest Heart Pump

Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.

Abiomed's (ABMD) Q1 Earnings and Revenues Beat, Margins Up

Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2022 Results - Earnings Call Transcript

Abiomed (ABMD) delivered earnings and revenue surprises of 3.77% and 3.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) Beats Q1 Earnings and Revenue Estimates

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces record revenue of $253 million, up 53% year over year.

Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year

Abiomed (ABMD) Reports Next Week: Wall Street Expects Earnings Growth

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.

Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to release financial results for the first quarter of the fiscal year 2022 on Thursday, August 5, 2021.

Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification

Abiomed has commenced its path to recovery on the charts, following a big hit in April this year. Key tension points for ABMD's share price lie in its Impella sales volume, which continues to gain traction sequentially as we walk through this year.

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Abiomed's (ABMD) Impella RP with SmartAssist gets the highest level of approval from the FDA for treatment of right heart failure.

Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed's (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart failure for up to 14 days. Impella RP with SmartAssist is the first single-access temporary percutaneous ventricular support device with dual-sensor technology. Impella RP with SmartAssist is an innovative advancement of Impella RP, which was granted a PM

News for ABIOMED Stock (ABMD)